[Economic assessment of pulsed dose-rate (PDR) brachytherapy with optimized dose distribution for cervix carcinoma]. 2010

R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
Université de Lyon, France. remonnay@lyon.fnclcc.fr

OBJECTIVE Our study aims at evaluating the cost of pulsed dose-rate (PDR) brachytherapy with optimized dose distribution versus traditional treatments (iridium wires, cesium, non-optimized PDR). Issues surrounding reimbursement were also explored. METHODS This prospective, multicentre, non-randomised study conducted in the framework of a project entitled "Support Program for Costly Diagnostic and Therapeutic Innovations" involved 21 hospitals. Patients with cervix carcinoma received either classical brachytherapy or the innovation. The direct medical costs of staff and equipment, as well as the costs of radioactive sources, consumables and building renovation were evaluated from a hospital point of view using a microcosting approach. Subsequent costs per brachytherapy were compared between the four strategies. RESULTS The economic study included 463 patients over two years. The main resources categories associated with PDR brachytherapy (whether optimized or not) were radioactive sources (1053euro) and source projectors (735euro). Optimized PDR induced higher cost of imagery and dosimetry (respectively 130euro and 367euro) than non-optimized PDR (47euro and 75euro). Extra costs of innovation over the less costly strategy (iridium wires) reached more than 2100euro per treatment, but could be reduced by half in the hypothesis of 40 patients treated per year (instead of 24 in the study). CONCLUSIONS Aside from staff, imaging and dosimetry, the current hospital reimbursements largely underestimated the cost of innovation related to equipment and sources.

UI MeSH Term Description Entries
D007349 Insurance, Health, Reimbursement Payment by a third-party payer in a sum equal to the amount expended by a health care provider or facility for health services rendered to an insured or program beneficiary. (From Facts on File Dictionary of Health Care Management, 1988) Health Insurance Reimbursement,Reimbursement, Health Insurance,Third-Party Payments,Third-Party Payers,Health Insurance Reimbursements,Insurance Reimbursement, Health,Insurance Reimbursements, Health,Payer, Third-Party,Payers, Third-Party,Payment, Third-Party,Payments, Third-Party,Reimbursements, Health Insurance,Third Party Payers,Third Party Payments,Third-Party Payer,Third-Party Payment
D007496 Iridium Radioisotopes Unstable isotopes of iridium that decay or disintegrate emitting radiation. Ir atoms with atomic weights 182-190, 192, and 194-198 are radioactive iridium isotopes. Radioisotopes, Iridium
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011874 Radiometry The measurement of radiation by photography, as in x-ray film and film badge, by Geiger-Mueller tube, and by SCINTILLATION COUNTING. Geiger-Mueller Counters,Nuclear Track Detection,Radiation Dosimetry,Dosimetry, Radiation,Geiger Counter,Geiger-Mueller Counter Tube,Geiger-Mueller Probe,Geiger-Mueller Tube,Radiation Counter,Counter Tube, Geiger-Mueller,Counter Tubes, Geiger-Mueller,Counter, Geiger,Counter, Radiation,Counters, Geiger,Counters, Geiger-Mueller,Counters, Radiation,Detection, Nuclear Track,Dosimetries, Radiation,Geiger Counters,Geiger Mueller Counter Tube,Geiger Mueller Counters,Geiger Mueller Probe,Geiger Mueller Tube,Geiger-Mueller Counter Tubes,Geiger-Mueller Probes,Geiger-Mueller Tubes,Probe, Geiger-Mueller,Probes, Geiger-Mueller,Radiation Counters,Radiation Dosimetries,Tube, Geiger-Mueller,Tube, Geiger-Mueller Counter,Tubes, Geiger-Mueller,Tubes, Geiger-Mueller Counter
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001918 Brachytherapy A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues. Curietherapy,Implant Radiotherapy,Plaque Therapy, Radioisotope,Radioisotope Brachytherapy,Radiotherapy, Interstitial,Radiotherapy, Intracavity,Radiotherapy, Surface,Brachytherapy, Radioisotope,Interstitial Radiotherapy,Intracavity Radiotherapy,Radioisotope Plaque Therapy,Radiotherapy, Implant,Surface Radiotherapy,Therapy, Radioisotope Plaque
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D002588 Cesium Radioisotopes Unstable isotopes of cesium that decay or disintegrate emitting radiation. Cs atoms with atomic weights of 123, 125-132, and 134-145 are radioactive cesium isotopes. Radioisotopes, Cesium
D003365 Costs and Cost Analysis Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs. Affordability,Analysis, Cost,Cost,Cost Analysis,Cost Comparison,Cost Measures,Cost-Minimization Analysis,Costs and Cost Analyses,Costs, Cost Analysis,Pricing,Affordabilities,Analyses, Cost,Analyses, Cost-Minimization,Analysis, Cost-Minimization,Comparison, Cost,Comparisons, Cost,Cost Analyses,Cost Comparisons,Cost Measure,Cost Minimization Analysis,Cost, Cost Analysis,Cost-Minimization Analyses,Costs,Measure, Cost,Measures, Cost

Related Publications

R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
November 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
January 1999, International journal of radiation oncology, biology, physics,
R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
September 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
December 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
January 2012, Brachytherapy,
R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
November 1994, The British journal of radiology,
R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
November 1993, Current opinion in oncology,
R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
August 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
January 2007, Acta oncologica (Stockholm, Sweden),
R Remonnay, and M Morelle, and P Pommier, and C Haie-Meder, and P Quetin, and C Kerr, and M Delannes, and B Castelain, and K Peignaux, and Y Kirova, and P Romestaing, and D Williaume, and C Krzisch, and L Thomas, and P Lang, and M H Baron, and A Cussac, and F Lesaunier, and S Maillard, and I Barillot, and C Charra-Brunaud, and M-O Carrère, and D Peiffert
June 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Copied contents to your clipboard!